Fusion protein to target and treat acute myeloid leukemia cells

Patent metadata

Field	Value
Publication number	US-10072093-B2
Application number	US-201414901016-A
Country	US
Kind code	B2
Filing date	Jul 4, 2014
Priority date	Jul 4, 2013
Publication date	Sep 11, 2018
Grant date	Sep 11, 2018

Abstract

A polypeptide which binds to the surface of AML blast cells and is internalized upon binding to the AML blast cells.

First claim

The invention claimed is:

1. A compound comprising:
a domain comprising a polypeptide which binds to the surface of AML blast cells and is internalised upon binding to the AML blast cells, and
a cytotoxic domain;
wherein the compound is a fusion polypeptide with the amino acid sequence of SEQ ID NO: 43.

2. A pharmaceutical composition comprising the compound of claim 1 .

Assignees

• Fraunhofer Ges Forschung
• Rheinisch Westfaelische Technische Hochschule Aachen
• Rheinisch Westfalische Technische Hochschule Aachen

Inventors

• Barth Stefan
• Fitting Jenny
• Tur Mehmet Kemal

Classifications

• C07K2317/56

  variable (Fv) region, i.e. VH and/or VL · CPC title

• C12N9/1077

  Pentosyltransferases (2.4.2) · CPC title

• C07K2317/73

  Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation · CPC title

• A61P35/02

  specific for leukemia · CPC title

• C07K2317/565

  Complementarity determining region [CDR] · CPC title